Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT

Completed · Phase 4

Conditions studied: Uterine Atony, Postpartum Hemorrhage

In brief

This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.

Key facts

Study ID

NCT00790062

Run by

University of Alabama at Birmingham

People needed

1798

Starts

2008-11-01

Expected to finish

2010-06-01

Last updated by the study team

2016-04-08

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• > 24 weeks, viable pregnancy, singleton or twins

You may not qualify if…

• No consent
• Contraindication to oxytocin
• Antepartum fetal demise
• Intrapartum use of concentrated oxytocin
• Planned cesarean
• DIC or coagulopathy

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.